Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Seeks Partners for Rheumatoid Arthritis Guideline Project

Staff  |  Issue: May 2013  |  May 1, 2013

ACR Seeks Partners for New RA Guideline Project

click for large version
RA Classification Tree: Tree algorithm for classifying definite rheumatoid arthritis (RA) (green circles) or for excluding its current presence (red circles) among those who are eligible to be assessed by the new criteria. APR=acute-phase response. Serology: + = low-positive for rheumatoid factor (RF) or anti–citrullinated protein antibody (ACPA); serology: ++ = high-positive for RF or ACPA; serology: +/++ = serology either + or ++.

The ACR is soliciting letters of interest from teams or individuals who wish to partner with the ACR in developing new clinical practice guidelines for rheumatoid arthritis (RA). The scope will broadly cover the use of corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics, including newer oral agents. The detailed questions to be answered by the guidelines will be decided by the ACR and project leaders once the guideline development team has been confirmed. ACR members will also be given an opportunity to publicly comment on the project scope and clinical questions via an online mechanism later this year.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The guidelines will be developed primarily for specialists who care for RA patients, but may also be used by primary care providers and others who care for these patients. The guidelines will be developed in accordance with the ACR’s standardized approach, which includes use of the Grades of Recommendation Assessment, Development, and Evaluation (GRADE) methodology.

Last March, the ACR posted online a public call for formal letters of interest, which are due no later than July 15, 2013. Guideline development partners who are chosen to work with the ACR will be expected to comply with all ACR policies and processes, as outlined in the ACR Guideline Manual.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The new RA guidelines are expected to be published no later than early 2015, and possibly as early as December 2014. The ACR will post a confirmed publication date on the Clinical Practice Guidelines page of www.rheumatology.org/Practice as soon as that date is available—likely in late summer or fall 2014.

For information regarding the request for letters of interest and to download the ACR Guideline Manual, visit www.rheumatology.org/Practice and click on “Clinical Support.”

Share: 

Filed under:From the College Tagged with:AC&RguidelineRheumatoid arthritis

Related Articles

    Researchers Seek to Predict & Prevent Rheumatoid Arthritis

    June 21, 2018

    Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…

    The Why & What of the ACR's Clinical Practice Guidelines

    The Why & What of the ACR’s Clinical Practice Guidelines

    February 18, 2018

    With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…

    Antibodies Can Spot RA in the General Population

    May 9, 2016

    NEW YORK (Reuters Health)—Anti-citrullinated protein antibodies (ACPA), particularly high anti-CCP2 titers, can diagnose rheumatoid arthritis (RA) in the general population with a high degree of accuracy, a Swedish study suggests. ACPA are highly specific for RA, but until now the diagnostic accuracy of ACPA in the general population has not been “thoroughly assessed,” note Dr….

    Plasma Cells, Synovial Compartment Implicated in Tenacity of Rheumatoid Arthritis

    October 10, 2016

    LONDON—New research shows that the synovial compartment appears to have a special role in the chronic nature of rheumatoid arthritis (RA), providing refuge for plasma cells and giving them an ideal environment in which to produce antibodies against citrullinated protein antigens (ACPA). The findings were presented at the Annual Congress of the European League Against…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences